18 F-PSMA-1007 and 18 F-FDG PET/CT in patients with prostate cancer

Abstract

Purpose To explore the value of 18F-PSMA-1007 and 18F-FDG PET/CT in prostate cancer （PCa） patients, this study compared the performance of the two tracers to detect PCa and then analyzed the correlation between the metabolic parameters and serum PSA value. Finally, we evaluated the application of both tracers in the auxiliary staging of PCa patients. Methods Thirty patients diagnosed with PCa who underwent both 18F-PSMA-1007 and 18F-FDG PET/CT were enrolled. The detection rate, number, location of lesions, and metabolic parameters SUVs (SUVmax, SUVmean), PSMA-TV, MTV, TL-PSMA, TLG, and tumor-to-background ratio (TBR) were recorded and compared. The correlation between metabolic parameters and serum PSA was analyzed. Finally, the differences and consistency of both tracers for the same patient’s NM stage and clinical stage were compared. Results Patient analysis showed that 18F-PSMA-1007 PET/CT had a similar ability to identify the primary tumor and local recurrence (p=1.000) as 18F-FDG PET/CT but identified more patients with metastases (p=0.016), especially bone metastases (p=0.004). Lesion analysis showed that 18F-PSMA-1007 PET/CT identified more primary lesions, local recurrences, and metastases. It also had higher diagnostic efficacy for lymph nodes and bone metastases (both p<0.05). For lesions with positive uptake, the median SUVs and TBR of 18F-PSMA-1007 PET/CT were significantly higher than 18F-FDG PET/CT (all p<0.05). The median PSMA-TV was higher than the median MTV. Still, the difference was not statistically significant (p>0.05), while the median TL-PSMA was significantly higher than the median TLG (p<0.05). Volume-based metabolic parameters PSMA-TV, TL-PSMA, MTV, and TLG, were significantly and positively correlated with PSA (all p<0.05). In contrast, SUVs and TBR for the primary tumor or local recurrence were not associated with PSA. 18F-PSMA-1007 PET/CT identified more M1 patients and higher clinical stage, and it had higher diagnostic efficacy than 18F-FDG PET/CT (p<0.05). Conclusions 18F-PSMA-1007 PET/CT was a valuable imaging modality for PCa. It had better diagnostic efficacy, lesions detection, and a higher median value for metabolic parameters than 18F-FDG PET/CT. Volume-based metabolic parameters reflecting the total tumor burden were positively correlated with serum PSA levels. 18F-PSMA-1007 PET/CT had a higher clinical application value than 18F-FDG PET/CT for PCa patients.

The impact of 18F-fluorodeoxyglucose PET/computed tomography on clinical staging in bladder cancer

“…The role of 18 F-FDG PET/CT imaging in bladder cancer has been evaluated in different studies published in recent years [13,[24][25][26]. Most researchers think that the role of 18 F-FDG in the diagnosis and follow-up of urological tumors is limited due to its urinary excretion [27,28].…”

Diagnostic Accuracy of Molecular Imaging Techniques for Detecting Prostate Cancer: A Systematic Review

“…In a comprehensive exploration of 18 F-PSMA-1007 PET/CT applications in PCa, studies consistently highlight its diagnostic superiority in various contexts. Liu et al, 2023, found that 18 F-PSMA-1007 PET/CT outperformed 18 F-FDG PET/CT with a high accuracy of 99%, sensitivity of 100%, and specificity of 97% in detecting primary PCa lesions [45]. Ferraro et al, 2022, demonstrated the efficacy of 18 F-PSMA-1007 PET/CT-guided biopsy for accurate lesion sampling intraoperatively [46].…”

Aerobic exercise, an effective prevention and treatment for mild cognitive impairment

“…On the other hand, they improve the inflammatory environment and alleviate the inflammatory microenvironment in the brain (Townsend et al, 2021). These factors mainly include irisin, cathepsin B (CTSB), CLU, and glycosylphosphatidylinositol-specific phospholipase D1 (GPLD1) (Lu et al, 2023). These exercise factors can protect the normal structure of the brain and enhance cognitive function through all the processes mentioned above.…”

“…It crosses the BBB through the circulatory system into the central nervous system. It activates the cAMP/PKA/CREB and MAPK/ERK pathways, increasing BDNF in neurons (Chen et al, 2022;Lu et al, 2023). Recent studies have found that the cAMP/PKA/CREB pathway can reduce the burden of neural tangles in the brain by inhibiting the transcription and expression of tau proteins (Lu et al, 2023).…”

“…It activates the cAMP/PKA/CREB and MAPK/ERK pathways, increasing BDNF in neurons (Chen et al, 2022;Lu et al, 2023). Recent studies have found that the cAMP/PKA/CREB pathway can reduce the burden of neural tangles in the brain by inhibiting the transcription and expression of tau proteins (Lu et al, 2023). In addition, inhibition of this pathway may also modulate brain 10.3389/fnagi.2023.1194559 FIGURE 4 Crosstalk between brain and exercise-induced factors.…”